Gene therapies' uneven delivery: How systemic inequities in precision medicine deepen health disparities and who benefits from the 'revolution'
Original framing: “Medicine's next leap: Delivering gene therapies exactly where they're needed” — Phys.org
The piece accurately describes the technical challenge of delivering gene therapies to hard‑to‑target organs and links it to corporate R&D priorities. It references regulatory capture and profit‑driven models, grounding its critique in observable industry practices. However, it offers limited quantitative data on efficacy, cost, or distribution, leaving the scientific argument more narrative than empirical.
The article reveals how scientific breakthroughs in gene therapy are entangled with historical patterns of exploitation, corporate capture, and global inequity, while largely omitting Indigenous, artistic, and nuanced cross‑cultural insights.
By foregrounding marginalised voices and employing a trickster lens, we see that the promised precision revolution risks reinforcing existing power asymmetries unless future modelling incorporates equity‑focused policies. Systemic solutions—ranging from pooled funding and community‑governed trials to globally harmonised regulations and Indigenous co‑design—can re‑anchor the technology within a justice‑oriented framework, turning a potential health divide into an opportunity for inclusive innovation.